AMARILLO, TX--(MARKET WIRE)--Aug 24, 2007 -- Amarillo Biosciences, Inc. (ABI) (OTC BB:AMAR.OB - News) today announced the following developments: In Turkey, enrollment is 78% complete in a Phase 2 study of Behçet’s disease. In the United States, patients have been enrolled to date in a Phase 2 clinical trial of oral warts. In Australia, a human influenza study is planned in 2008. In Taiwan and China, ABI’s Taiwanese partners are expected to conduct a clinical trial in chronic active hepatitis C patients. These developments will help pave the way for the realization of the Company’s ultimate goal: FDA approval for its low-dose oral interferon.
